All In Biotech

Drug Trial Radar · NCT02499328

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.

Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 340 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

340

Actual

Start

Aug 6, 2015

Primary completion

Feb 28, 2020

Study completion Oct 8, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
MedImmune LLC
First posted
Jul 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B

Conditions

  • Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck

Interventions

  • AZD9150Drug

    AZD9150

  • MEDI4736Drug

    MEDI4736

  • AZD5069Drug

    AZD5069

  • tremelimumab (treme)Drug

    tremelimumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Danvatirsen With Durvalumab MTDs (Maximum Tolerated Dose) or Recommended Doses for Dose-expansionTime frame: 35 days
  2. Part A: AZD5069 With Durvalumab MTDs (Maximum Tolerated Dose) or Recommended Doses for Dose-expansionTime frame: 35 days
  3. Part A: Safety and Tolerability in Terms of Adverse EventsTime frame: At every treatment and follow up visit until disease progression, an average of 1 year.
  4. Part B: ORR (Objective Response Rate) in Patients With IL/2L RM-SCCHN.Time frame: Assessed at every even-numbered cycles with RECIST until disease progression, up to 12 months.

Locations

44 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Duarte, California

  • Research Site

    La Jolla, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Orange, California

  • Research Site

    San Francisco, California

  • Research Site

    Denver, Colorado

  • Research Site

    Plantation, Florida

  • Research Site

    Sarasota, Florida

  • Research Site

    Lafayette, Indiana

  • Research Site

    Boston, Massachusetts

  • Research Site

    Detroit, Michigan

  • Research Site

    Billings, Montana

  • Research Site

    Morristown, New Jersey

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Houston, Texas

  • Research Site

    Fairfax, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Antwerp, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Edegem, Belgium

  • Research Site

    Namur, Belgium

  • Research Site

    Berlin, Germany

  • Research Site

    Cologne, Germany

  • Research Site

    Dresden, Germany

  • Research Site

    Frankfurt, Germany

  • Research Site

    Hamburg, Germany

  • Research Site

    Hanover, Germany

  • Research Site

    Jena, Germany

  • Research Site

    München, Germany

  • Research Site

    Milan, Italy

  • Research Site

    Barcelona, Spain

  • Research Site

    Hospitalet deLlobregat, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Toledo, Spain

  • Research Site

    Birmingham, United Kingdom

  • Research Site

    London, United Kingdom

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.